Q3 EPS Estimates for OTCMKTS:BIOVF Cut by HC Wainwright

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) – Investment analysts at HC Wainwright dropped their Q3 2026 EPS estimates for shares of Swedish Orphan Biovitrum in a research note issued to investors on Friday, July 17th. HC Wainwright analyst M. Kapoor now expects that the company will earn $0.63 per share for the quarter, down from their previous estimate of $0.69. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Swedish Orphan Biovitrum’s Q4 2026 earnings at $0.60 EPS, FY2026 earnings at $1.94 EPS, Q1 2027 earnings at $0.62 EPS, Q2 2027 earnings at $0.68 EPS, Q3 2027 earnings at $1.05 EPS, Q4 2027 earnings at $1.03 EPS and FY2027 earnings at $3.36 EPS.

BIOVF has been the subject of several other research reports. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Finally, Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, May 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

Shares of BIOVF stock opened at $49.03 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47. Swedish Orphan Biovitrum has a one year low of $28.93 and a one year high of $49.03. The company’s fifty day moving average price is $47.99 and its 200-day moving average price is $42.30. The company has a market capitalization of $17.45 billion, a price-to-earnings ratio of 108.95 and a beta of 0.35.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.07. The business had revenue of $755.76 million for the quarter, compared to the consensus estimate of $749.76 million. Swedish Orphan Biovitrum had a net margin of 4.74% and a return on equity of 18.27%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.